Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, today announced the closing of a $12M Seed financing round. The round was led by Khosla Ventures, with participation from Longevity Fund, Refactor Capital, Shanda and additional investors.

The funding will be used to advance the company's lead candidates in respiratory diseases with significant unmet medical need, such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). In addition, Rubedo will advance preclinical candidates in oncology, followed by neurodegenerative conditions, skeletal muscle disorders and other age-related diseases. The company plans to advance several compounds into IND-enabling studies in pulmonary diseases starting next year.

Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, technology, and life sciences, with expertise in drug development and commercialization from both large pharma and leading biotech companies. The company is based in Sunnyvale, CA. For additional information, please visit www.rubedolife.com.